Xenon Pharmaceuticals
XENE
206 hedge funds and large institutions have $2.95B invested in Xenon Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 77 increasing their positions, 62 reducing their positions, and 24 closing their positions.
321% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $1.13M
24% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 62
15% more capital inflows, than outflows
Capital inflows: $264M | Capital outflows: $230M
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
0.56% more ownership
Funds ownership: 98.29% → 98.85% (+0.56%)
4% less funds holding
Funds holding: 214 → 206 (-8)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$60.8M |
| 2 |
JP Morgan Chase
New York
|
+$36.5M |
| 3 |
Samlyn Capital
New York
|
+$15.3M |
| 4 |
Vestal Point Capital
New York
|
+$12.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
-$79.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$26.2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$14.9M |
| 4 |
Logos Global Management
San Francisco,
California
|
-$14.6M |
| 5 |
Boone Capital Management
Atlanta,
Georgia
|
-$9.8M |
XENE Hedge Fund Activity: Q3 2024 in Review
206 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2024, worth a combined $2.95B — up 2% from $2.89B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of XENE and 16 opened new positions — a net loss of 8 holders — while 62 trimmed existing stakes and 77 added.
The largest buyer was Janus Henderson Group, adding an estimated $60.8M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $79.7M sold.
- 206 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2024, down from 214 in Q2 2024.
- Funds reported $2.95B of Xenon Pharmaceuticals stock for Q3 2024, up 2% quarter-over-quarter.
- 16 funds opened new Xenon Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of -8 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2024 was Janus Henderson Group, an estimated $60.8M added.
- The largest Xenon Pharmaceuticals seller in Q3 2024 was Paradigm Biocapital Advisors, an estimated $79.7M sold.
Based on aggregated 13F filings for Q3 2024.